Clinical Trial Update: Nicotine Treatment of Cognitive Decline in Down Syndrome [Phase 1, Phase 2]

View source ↗

Summary

A completed phase 1/2 clinical trial evaluating nicotine treatment for cognitive decline in individuals with Down syndrome and mild cognitive impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Down Syndrome

Drugs mentioned

• Nicotine (nicotine)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Down Syndrome, Mild Cognitive Impairment | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-10